Secondary glioblastoma patients are generally younger (mean age, 45–48 years), and their tumors are characterized by TP53 mutations, 1p19q loss and isocitrate dehydrogenase (IDH) mutations, the latter suggested to be present in 70–80% of cases [3]. Here, IDH2 is linked to glioblastoma.